Treats osteoarthritis of the knee(s). ANDA 205878, held by Novel Labs Inc. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 205878 (Diclofenac Sodium), held by Novel Labs Inc, was first approved by FDA on Dec 9, 2015, with 3 approved supplements and 0 published complete response letters.
Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 9, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1.5% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 14, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 9, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters